LGVN
Price:
$1.97
Market Cap:
$28.29M
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.[Read more]
Industry
Biotechnology
IPO Date
2021-02-12
Stock Exchange
NASDAQ
Ticker
LGVN
According to Longeveron Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.22. This represents a change of -80.96% compared to the average of -1.16 of the last 4 quarters.
The mean historical PE Ratio of Longeveron Inc. over the last ten years is -48.30. The current -0.22 PE Ratio has changed -54.46% with respect to the historical average. Over the past ten years (40 quarters), LGVN's PE Ratio was at its highest in in the March 2024 quarter at -0.44. The PE Ratio was at its lowest in in the March 2020 quarter at -1393.07.
Average
-48.30
Median
-25.87
Minimum
-186.01
Maximum
-1.38
Discovering the peaks and valleys of Longeveron Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -1.38
Minimum Annual Increase = -76.57%
Minimum Annual PE Ratio = -186.01
Year | PE Ratio | Change |
---|---|---|
2023 | -1.38 | -59.87% |
2022 | -3.44 | -76.57% |
2021 | -14.68 | -60.37% |
2020 | -37.05 | -21.60% |
2019 | -47.26 | -74.59% |
The current PE Ratio of Longeveron Inc. (LGVN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-6.50
5-year avg
-20.76
10-year avg
-48.30
Longeveron Inc.’s PE Ratio is greater than Nutriband Inc. (-6.76), greater than Quoin Pharmaceuticals, Ltd. (-0.47), greater than RenovoRx, Inc. (-3.02), greater than Virax Biolabs Group Limited (-1.34), greater than Generation Bio Co. (-0.92), greater than Kronos Bio, Inc. (-0.58), greater than Erasca, Inc. (-3.94), greater than C4 Therapeutics, Inc. (-3.44), greater than Edgewise Therapeutics, Inc. (-14.14), greater than Surrozen, Inc. (-0.55), greater than Bolt Biotherapeutics, Inc. (-0.37), greater than Larimar Therapeutics, Inc. (-8.80), greater than Keros Therapeutics, Inc. (-11.28), greater than Kezar Life Sciences, Inc. (-0.41), less than Blue Water Vaccines, Inc. (-0.17), less than Revelation Biosciences, Inc. (-0.09), less than Hillstream BioPharma, Inc. (-0.00), less than Kiora Pharmaceuticals, Inc. (4.61), greater than ABVC BioPharma, Inc. (-0.66), greater than Indaptus Therapeutics, Inc. (-0.78), greater than Pasithea Therapeutics Corp. (-0.27), less than Better Therapeutics, Inc. (-0.00), greater than Forte Biosciences, Inc. (-0.39),
Company | PE Ratio | Market cap |
---|---|---|
-6.76 | $49.16M | |
-0.47 | $3.06M | |
-3.02 | $24.47M | |
-1.34 | $15.24M | |
-0.92 | $145.50M | |
-0.58 | $59.36M | |
-3.94 | $807.96M | |
-3.44 | $374.42M | |
-14.14 | $1.64B | |
-0.55 | $29.60M | |
-0.37 | $24.78M | |
-8.80 | $513.64M | |
-11.28 | $1.97B | |
-0.41 | $40.82M | |
-0.17 | $3.41M | |
-0.09 | $1.43M | |
-0.00 | $4.17M | |
4.61 | $10.52M | |
-0.66 | $8.19M | |
-0.78 | $14.58M | |
-0.27 | $4.37M | |
-0.00 | $5.45K | |
-0.39 | $11.11M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Longeveron Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Longeveron Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Longeveron Inc.'s PE Ratio?
How is the PE Ratio calculated for Longeveron Inc. (LGVN)?
What is the highest PE Ratio for Longeveron Inc. (LGVN)?
What is the 3-year average PE Ratio for Longeveron Inc. (LGVN)?
What is the 5-year average PE Ratio for Longeveron Inc. (LGVN)?
How does the current PE Ratio for Longeveron Inc. (LGVN) compare to its historical average?